The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Vertex Pharmaceuticals Inc

Nasdaq: VRTX
Last

(U.S.) $134.05

Today's change+0.30 +0.22%
Updated August 28 4:15 PM EDT. Delayed by at least 15 minutes.
 

Vertex Pharmaceuticals Inc

Nasdaq: VRTX
Last

(U.S.) $134.05

Today's change+0.30 +0.22%
Updated August 28 4:15 PM EDT. Delayed by at least 15 minutes.

Vertex Pharmaceuticals Inc up (U.S.)$0.30

Vertex Pharmaceuticals Inc closed up Friday by (U.S.)$0.30 or 0.22% to (U.S.)$134.05. Over the last five days, shares have gained 6.84% and 12.84% year to date. Shares have outperformed the S&P 500 by 44.84% during the last year.

Key company metrics

  • Open(U.S.) $132.39
  • Previous close(U.S.) $133.75
  • High(U.S.) $134.53
  • Low(U.S.) $131.03
  • Bid / Ask-- / --
  • YTD % change+12.84%
  • Volume1,240,196
  • Average volume (10-day)1,921,499
  • Average volume (1-month)1,815,093
  • Average volume (3-month)1,600,230
  • 52-week range(U.S.) $90.99 to (U.S.) $143.45
  • Beta0.21
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$3.07
Updated August 28 4:15 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-122.64%

Although this company's net profit margin is negative, it is above the industry average and implies that Vertex Pharmaceuticals Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.71%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2015Q1/2015Q4/2014Q3/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014
Revenue166139145179
Total other revenue--------
Total revenue166139145179
Gross profit151129133169
Total cost of revenue1591110
Total operating expense337310298321
Selling / general / administrative94867975
Research & development224216201191
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)2-3441
Other operating expenses, total1334
Operating income-171-172-154-142
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-191-198-179-167
Income after tax-221-199-181-170
Income tax, total30023
Net income-189-199-177-170
Total adjustments to net income--------
Net income before extra. items-189-199-176-170
Minority interest32040
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-189-199-176-170
Inc. avail. to common incl. extra. items-189-199-177-170
Diluted net income-189-199-177-170
Dilution adjustment--------
Diluted weighted average shares241239239236
Diluted EPS excluding extraordinary itemsvalue per share-0.78-0.83-0.74-0.72
Dividends per sharevalue per share0.000.00--0.00
Diluted normalized EPSvalue per share-0.78-0.84-0.73-0.61